Bell Palsy: What the Steroid and Antiviral Evidence Shows

What does the evidence say about treating Bell palsy?#

Two drugs are commonly discussed for new-onset Bell palsy, and the evidence treats them very differently. Corticosteroids receive the American Academy of Neurology's strongest recommendation tier (Level A), meaning they should be offered because well-designed trials show they improve the odds of facial recovery. Antivirals sit near the bottom (Level C), meaning any added benefit is uncertain and, at most, small. The interesting part is not just the conclusion but the reason for it, because the same guideline reaches opposite verdicts on two reasonable-sounding treatments.

Key points#

• Corticosteroids for new-onset Bell palsy carry a Level A recommendation, the guideline's highest tier.
• Antivirals carry only a Level C recommendation; a benefit beyond steroids has not been established.
• The difference comes from trial quality and effect size, not from which idea sounds more plausible.
• The verbs in a guideline ("should be offered" versus "might be offered") encode how strong the evidence is.

Start with the scoring system, not the drugs#

It is tempting to jump straight to which pill wins, but the recommendations only make sense once you know how the grades are assigned. The AAN uses a two-step method. First it rates each individual trial by how well it guards against bias, from Class I (the most protected) down to Class IV (the least). Then it pools that body of evidence into a single recommendation letter, from A (strong support) down to U (evidence insufficient to decide).

Think of the letter grade as a confidence rating on the evidence itself, not a measure of how excited anyone is about the treatment. A Level A verdict says several strong, agreeing trials back the action. A Level C verdict says the support is thinner, more mixed, or capped at a small effect. The guideline reviewed by Gronseth and Paduga applied exactly this scheme to Bell palsy, and the two drugs came out on opposite ends of it.

A quick word on Bell palsy itself#

Bell palsy is a sudden weakness or drooping of the muscles on one side of the face, caused by trouble with the facial nerve. It usually develops over hours to a day or two. The cause is not fully settled, though swelling of the nerve inside a tight bony channel features in most explanations, and reactivation of a dormant herpes simplex virus has long been floated as a trigger.

One feature of the condition shapes everything about the evidence: many people recover on their own. A favorable natural history sets a high bar, because any treatment has to prove it does better than simply waiting. That is precisely what the trials tried to measure.

Why corticosteroids clear the bar#

The steroid recommendation rests on two Class I trials, meaning two low-bias randomized studies that pointed the same way. When strong trials agree, the scoring system permits its top grade. Both studies found that patients given corticosteroids were more likely to regain facial function than those who were not, with a risk difference somewhere in the range of about 13 to 15 percent favoring treatment.

It helps to picture what a number like that buys. A risk difference in that range means that for roughly every hundred patients treated, about a dozen more recover facial movement who might not have otherwise. That is a real, clinically meaningful effect, and the agreement between two solid trials is what lets the guideline say steroids should be offered rather than the softer might be considered. Guideline verbs are chosen with care, and this one signals genuine confidence.

Why antivirals fall short#

Antivirals looked like a sensible thing to test. If a reactivated virus helps set off Bell palsy, a drug that suppresses that virus should logically help. Biological plausibility, though, is a hypothesis, not a result, and the trials did not deliver the hoped-for benefit.

The guideline concluded that adding an antiviral to steroids raises the chance of facial recovery by no more than about 7 percent, and possibly not at all. Read that ceiling carefully. It is not a flat declaration that antivirals do nothing; it is a statement about how large any extra benefit could plausibly be, and that upper bound is low. On that basis antivirals landed at Level C, with nuanced advice: a patient might be offered one in addition to steroids, but should be told that no benefit is established and that any real effect is likely modest.

Notice the shape of the question too. The strong evidence is for steroids, so steroids are the anchor, and the antiviral trials ask only whether stacking a second drug on top adds anything. That framing is why the antiviral verdict is worded as an option rather than a recommendation.

How to read any recommendation level#

Bell palsy is a tidy worked example of a habit that pays off across all of medicine. A recommendation letter summarizes what the evidence can bear, not how appealing the underlying idea is. When a Level A and a Level C recommendation sit side by side for the same condition, the split almost always traces back to the trials, not to the biology.

Three quick reflexes help when you read any guideline:

• Check the studies behind the claim. Two Class I trials carry far more weight than a scattering of small, biased ones.
• Read the effect size, not just the direction. A tiny benefit and a large benefit are both technically positive, and they call for different decisions.
• Watch the verbs. "Should be offered," "might be offered," and "should not be offered" translate the strength of the evidence into plain language.

Putting it together#

If you have just been diagnosed with Bell palsy, the practical shape of the evidence is clear. The best-supported step is early corticosteroid treatment, backed by strong trials and a meaningful effect on recovery. Antivirals occupy an optional space, reasonable to discuss but not something the evidence firmly endorses. Every real decision still belongs in a conversation with the clinician treating you, who weighs timing, severity, and other health conditions that steroids can affect. The guideline sets the backdrop for that conversation; it does not replace it.